ALS (amyotrophic lateral sclerosis)

GPTKB entity

Predicate	Object
gptkbp:instanceOf	neurodegenerative disease
gptkbp:affects	central nervous system motor neurons peripheral nervous system
gptkbp:alsoKnownAs	gptkb:Lou_Gehrig's_disease
gptkbp:awarenessEvent	gptkb:ALS_Ice_Bucket_Challenge
gptkbp:casualties	yes
gptkbp:cause	difficulty breathing difficulty speaking difficulty swallowing muscle atrophy muscle weakness
gptkbp:diagnosedBy	gptkb:electromyography_(EMG) MRI clinical examination nerve conduction studies
gptkbp:firstDescribed	gptkb:Jean-Martin_Charcot
gptkbp:hereditary	about 5-10% of cases
https://www.w3.org/2000/01/rdf-schema#label	ALS (amyotrophic lateral sclerosis)
gptkbp:ICD-10_code	G12.2
gptkbp:incidence	about 2 per 100,000 people per year
gptkbp:medianSurvival	2-5 years after diagnosis
gptkbp:mutationAssociatedWith	gptkb:C9orf72 gptkb:FUS gptkb:SOD1 gptkb:TARDBP
gptkbp:namedAfter	gptkb:Lou_Gehrig
gptkbp:notablePatient	gptkb:Stephen_Hawking gptkb:Lou_Gehrig
gptkbp:onset	usually adult
gptkbp:prevalence	rare
gptkbp:prognosis	poor
gptkbp:progression	progressive
gptkbp:riskFactor	age family history genetic mutations
gptkbp:sporadic	about 90-95% of cases
gptkbp:studiedBy	ongoing
gptkbp:symptom	respiratory failure cramps muscle twitching spasticity difficulty walking slurred speech
gptkbp:treatment	gptkb:edaravone gptkb:riluzole supportive care physical therapy speech therapy ventilatory support
gptkbp:bfsParent	gptkb:Steve_Gleason
gptkbp:bfsLayer	5